Valuation: Keros Therapeutics, Inc.

Market Cap 206M 181M 167M 156M 292M 19.44B 298M 2B 774M 9.61B 774M 757M 33.31B P/E 2026 *
-1.74x
P/E 2027 * -1.91x
Enterprise Value 206M 181M 167M 156M 292M 19.44B 298M 2B 774M 9.61B 774M 757M 33.31B EV / Sales 2026 *
48.5x
EV / Sales 2027 * 10.9x
Free-Float
46.57%
Yield 2026 *
-
Yield 2027 * -
1 day-0.10%
1 week-5.92%
Current month-8.18%
1 month-8.01%
3 months-6.77%
6 months-50.88%
Current year-49.26%
1 week 10.3
Extreme 10.3
11.47
1 month 9.69
Extreme 9.69
11.63
Current year 9.69
Extreme 9.69
20.34
1 year 9.69
Extreme 9.69
22.55
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
73
10 years 9.12
Extreme 9.12
88.8
Manager TitleAgeSince
Chief Executive Officer 70 01/12/2015
Director of Finance/CFO 56 01/02/2020
Chief Tech/Sci/R&D Officer 53 01/06/2019
Director TitleAgeSince
Chairman 70 01/07/2024
Director/Board Member 63 01/04/2016
Director/Board Member 50 01/03/2020
Date Insider Type Main position Quantity % Market Cap.
06-15Buy

Chairman

1,000 0.0051%
06-11Sell

Director

-550 0.0028%
06-04Sell

Director

-2,625 0.0133%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-5.92%-23.54%-74.41% 206M
+0.33%+1.37%+64.03%+119.11% 55.35B
+0.82%+15.05%+74.28%+86.70% 51.92B
-0.85%-1.11%-15.97%-16.59% 22.76B
+1.45%+7.77%+4.45%+433.75% 22.64B
-0.18%+7.20%+28.56%-12.48% 17.36B
-1.10%+4.00%+28.70%-34.51% 16.1B
-3.35%+8.96%+135.18%+294.38% 13.96B
+2.24%+6.19%+26.55%+180.22% 13.38B
+1.31%+0.53%+27.21% - 12.27B
Average +0.06%+3.94%+34.95%+108.46% 22.59B
Weighted average by Cap. +0.24%+5.28%+47.21%+122.95%

Financials

2026 *2027 *
Net sales 4.25M 3.73M 3.44M 3.22M 6.03M 401M 6.16M 41.31M 15.98M 198M 15.97M 15.62M 687M 18.91M 16.58M 15.28M 14.31M 26.83M 1.78B 27.39M 184M 71.08M 882M 71.01M 69.46M 3.06B
Net income -120M -106M -97.35M -91.14M -171M -11.36B -174M -1.17B -453M -5.62B -452M -442M -19.47B -132M -116M -107M -99.86M -187M -12.45B -191M -1.28B -496M -6.15B -496M -485M -21.34B
Net Debt - -
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
87
Date Price Change Volume
26/06/26 $10.33 -0.77% 74,963
25/06/26 $10.41 -4.67% 267,196
24/06/26 $10.92 -0.73% 212,796
23/06/26 $11.00 +0.18% 267,994
22/06/26 $10.98 +3.10% 340,591
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.41USD
Average target price
21.83USD
Spread / Average Target
+109.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KROS Stock